227 related articles for article (PubMed ID: 33450669)
21. Dynamic Characteristic Analysis of Antibodies in Patients With COVID-19: A 13-Month Study.
Shi D; Weng T; Wu J; Dai C; Luo R; Chen K; Zhu M; Lu X; Cheng L; Chen Q; Liu F; Wu Z; Wu H; Jin C; Guo M; Chen Z; Wu N; Yao H; Zheng M
Front Immunol; 2021; 12():708184. PubMed ID: 34354712
[TBL] [Abstract][Full Text] [Related]
22. Declining Levels of Neutralizing Antibodies Against SARS-CoV-2 in Convalescent COVID-19 Patients One Year Post Symptom Onset.
Xiang T; Liang B; Fang Y; Lu S; Li S; Wang H; Li H; Yang X; Shen S; Zhu B; Wang B; Wu J; Liu J; Lu M; Yang D; Dittmer U; Trilling M; Deng F; Zheng X
Front Immunol; 2021; 12():708523. PubMed ID: 34220870
[TBL] [Abstract][Full Text] [Related]
23. Persisting Neutralizing Activity to SARS-CoV-2 over Months in Sera of COVID-19 Patients.
Flehmig B; Schindler M; Ruetalo N; Businger R; Bayer M; Haage A; Kirchner T; Klingel K; Normann A; Pridzun L; Tougianidou D; Ranke MB
Viruses; 2020 Nov; 12(12):. PubMed ID: 33260809
[TBL] [Abstract][Full Text] [Related]
24. SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection.
Havervall S; Jernbom Falk A; Klingström J; Ng H; Greilert-Norin N; Gabrielsson L; Salomonsson AC; Isaksson E; Rudberg AS; Hellström C; Andersson E; Olofsson J; Skoglund L; Yousef J; Pin E; Christ W; Olausson M; Hedhammar M; Tegel H; Mangsbo S; Phillipson M; Månberg A; Hober S; Nilsson P; Thålin C
PLoS One; 2022; 17(1):e0262169. PubMed ID: 35020778
[TBL] [Abstract][Full Text] [Related]
25. Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects.
Huynh A; Arnold DM; Smith JW; Moore JC; Zhang A; Chagla Z; Harvey BJ; Stacey HD; Ang JC; Clare R; Ivetic N; Chetty VT; Bowdish DME; Miller MS; Kelton JG; Nazy I
Viruses; 2021 Apr; 13(4):. PubMed ID: 33923828
[TBL] [Abstract][Full Text] [Related]
26. SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity.
Nielsen SS; Vibholm LK; Monrad I; Olesen R; Frattari GS; Pahus MH; Højen JF; Gunst JD; Erikstrup C; Holleufer A; Hartmann R; Østergaard L; Søgaard OS; Schleimann MH; Tolstrup M
EBioMedicine; 2021 Jun; 68():103410. PubMed ID: 34098342
[TBL] [Abstract][Full Text] [Related]
27. Long-Term Humoral Immune Response against SARS-CoV-2 after Natural Infection and Subsequent Vaccination According to WHO International Binding Antibody Units (BAU/mL).
Ruetalo N; Flehmig B; Schindler M; Pridzun L; Haage A; Reichenbächer M; Kirchner T; Kirchner T; Klingel K; Ranke MB; Normann A
Viruses; 2021 Nov; 13(12):. PubMed ID: 34960605
[TBL] [Abstract][Full Text] [Related]
28. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
Chi X; Yan R; Zhang J; Zhang G; Zhang Y; Hao M; Zhang Z; Fan P; Dong Y; Yang Y; Chen Z; Guo Y; Zhang J; Li Y; Song X; Chen Y; Xia L; Fu L; Hou L; Xu J; Yu C; Li J; Zhou Q; Chen W
Science; 2020 Aug; 369(6504):650-655. PubMed ID: 32571838
[TBL] [Abstract][Full Text] [Related]
29. SARS-CoV-2 antibodies: Comparison of three high-throughput immunoassays versus the neutralization test.
Laterza R; Schirinzi A; Bruno R; Genco R; Contino R; Ostuni A; Di Serio F
Eur J Clin Invest; 2021 Jul; 51(7):e13573. PubMed ID: 33870493
[No Abstract] [Full Text] [Related]
30. Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections.
Lei Q; Li Y; Hou HY; Wang F; Ouyang ZQ; Zhang Y; Lai DY; Banga Ndzouboukou JL; Xu ZW; Zhang B; Chen H; Xue JB; Lin XS; Zheng YX; Yao ZJ; Wang XN; Yu CZ; Jiang HW; Zhang HN; Qi H; Guo SJ; Huang SH; Sun ZY; Tao SC; Fan XL
Allergy; 2021 Feb; 76(2):551-561. PubMed ID: 33040337
[TBL] [Abstract][Full Text] [Related]
31. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.
Gallais F; Gantner P; Bruel T; Velay A; Planas D; Wendling MJ; Bayer S; Solis M; Laugel E; Reix N; Schneider A; Glady L; Panaget B; Collongues N; Partisani M; Lessinger JM; Fontanet A; Rey D; Hansmann Y; Kling-Pillitteri L; Schwartz O; De Sèze J; Meyer N; Gonzalez M; Schmidt-Mutter C; Fafi-Kremer S
EBioMedicine; 2021 Sep; 71():103561. PubMed ID: 34455390
[TBL] [Abstract][Full Text] [Related]
32. Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods.
Bošnjak B; Stein SC; Willenzon S; Cordes AK; Puppe W; Bernhardt G; Ravens I; Ritter C; Schultze-Florey CR; Gödecke N; Martens J; Kleine-Weber H; Hoffmann M; Cossmann A; Yilmaz M; Pink I; Hoeper MM; Behrens GMN; Pöhlmann S; Blasczyk R; Schulz TF; Förster R
Cell Mol Immunol; 2021 Apr; 18(4):936-944. PubMed ID: 33139905
[TBL] [Abstract][Full Text] [Related]
33. Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity.
Ripperger TJ; Uhrlaub JL; Watanabe M; Wong R; Castaneda Y; Pizzato HA; Thompson MR; Bradshaw C; Weinkauf CC; Bime C; Erickson HL; Knox K; Bixby B; Parthasarathy S; Chaudhary S; Natt B; Cristan E; El Aini T; Rischard F; Campion J; Chopra M; Insel M; Sam A; Knepler JL; Capaldi AP; Spier CM; Dake MD; Edwards T; Kaplan ME; Scott SJ; Hypes C; Mosier J; Harris DT; LaFleur BJ; Sprissler R; Nikolich-Žugich J; Bhattacharya D
Immunity; 2020 Nov; 53(5):925-933.e4. PubMed ID: 33129373
[TBL] [Abstract][Full Text] [Related]
34. Different Profiles of Antibodies and Cytokines Were Found Between Severe and Moderate COVID-19 Patients.
Guo Y; Li T; Xia X; Su B; Li H; Feng Y; Han J; Wang X; Jia L; Bao Z; Li J; Liu Y; Li L
Front Immunol; 2021; 12():723585. PubMed ID: 34489974
[TBL] [Abstract][Full Text] [Related]
35. An Integrated Platform for Serological Detection and Vaccination of COVID-19.
Wei SC; Hsu WT; Chiu CH; Chang FY; Lo HR; Liao CY; Yang HI; Chou YC; Tsai CH; Chao YC
Front Immunol; 2021; 12():771011. PubMed ID: 35003088
[TBL] [Abstract][Full Text] [Related]
36. COVID-19-neutralizing antibodies predict disease severity and survival.
Garcia-Beltran WF; Lam EC; Astudillo MG; Yang D; Miller TE; Feldman J; Hauser BM; Caradonna TM; Clayton KL; Nitido AD; Murali MR; Alter G; Charles RC; Dighe A; Branda JA; Lennerz JK; Lingwood D; Schmidt AG; Iafrate AJ; Balazs AB
Cell; 2021 Jan; 184(2):476-488.e11. PubMed ID: 33412089
[TBL] [Abstract][Full Text] [Related]
37. Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome.
Röltgen K; Powell AE; Wirz OF; Stevens BA; Hogan CA; Najeeb J; Hunter M; Wang H; Sahoo MK; Huang C; Yamamoto F; Manohar M; Manalac J; Otrelo-Cardoso AR; Pham TD; Rustagi A; Rogers AJ; Shah NH; Blish CA; Cochran JR; Jardetzky TS; Zehnder JL; Wang TT; Narasimhan B; Gombar S; Tibshirani R; Nadeau KC; Kim PS; Pinsky BA; Boyd SD
Sci Immunol; 2020 Dec; 5(54):. PubMed ID: 33288645
[TBL] [Abstract][Full Text] [Related]
38. A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity.
Legros V; Denolly S; Vogrig M; Boson B; Siret E; Rigaill J; Pillet S; Grattard F; Gonzalo S; Verhoeven P; Allatif O; Berthelot P; Pélissier C; Thiery G; Botelho-Nevers E; Millet G; Morel J; Paul S; Walzer T; Cosset FL; Bourlet T; Pozzetto B
Cell Mol Immunol; 2021 Feb; 18(2):318-327. PubMed ID: 33408342
[TBL] [Abstract][Full Text] [Related]
39. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
40. Durable antibody response one year after hospitalization for COVID-19: A longitudinal cohort study.
Masiá M; Fernández-González M; Telenti G; Agulló V; García JA; Padilla S; García-Abellán J; Galiana A; Gonzalo-Jiménez N; Gutiérrez F
J Autoimmun; 2021 Sep; 123():102703. PubMed ID: 34303083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
